Headlands Research, a portfolio company of KKR, announced the acquisition of AMCR Institute, which has been in operation for more than 20 years.
AMCR Institute is an Escondido, California-based clinical research site specializing in metabolic, endocrine and other chronic conditions such as diabetes and obesity. The company is led by principal investigator Dr. Timothy S. Bailey, a board-certified endocrinologist. He and his staff have worked with thousands of volunteers in phase I-IV trials and have extensive experience with the evaluation of medical devices such as continuous glucose monitors.
San Francisco-based Headlands Research is a globally integrated clinical trial site organization. Headlands Research has successfully completed more than 5,000 clinical trials.
The AMCR Institute team brings experience in metabolic, endocrine and medical device research to the Headlands Research network. Following the acquisition, AMCR Institute will be known as Headlands Research AMCR Institute. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this transaction represents the 20th clinical trials acquisition of 2023. This also marks Headlands Research’s third deal of 2023, and its fourth since June 2022. Earlier this year, Headlands Research acquired Plymouth, Massachusetts-based Headlands Research Eastern Massachusetts in April, followed by Springfield, Missouri-based Clinvest Research in May.
